Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy

Cancer Gene Therapy

Volumn 20, Issue 1, 2013, Pages 57-64

  Kanagawa, N ^a   Yanagawa, T ^a   Nakagawa, T ^a   Okada, N ^a   Nakagawa, S ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Chimeric T cell receptor; Cytotoxic T lymphocytes; Gene transduction; Vascular endothelial growth factor receptor

Indexed keywords

SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL ENGINEERING; CELL THERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION;

ADOPTIVE TRANSFER; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; T-LYMPHOCYTES, CYTOTOXIC; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; WOUND HEALING;

MUS;

EID: 84871994681     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.85     Document Type: Article

References (44)

1. Gattinoni L, Powell Jr DJ, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006; 6: 383-393.
2. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J Invest Dermatol 2008; 128: 2596-2605.
3. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS et al. Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst 1994; 86: 1159-1166.
4. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
5. Stauss HJ, Cesco-Gaspere M, Thomas S, Hart DP, Xue SA, Holler A et al. Monoclonal T-cell receptors: New reagents for cancer therapy. Mol Ther 2007; 15: 1744-1750.
6. de Witte MA, Jorritsma A, Kaiser A, van den Boom MD, Dokter M, Bendle GM et al. Requirements for effective antitumor responses of TCR transduced T cells. J Immunol 2008; 181: 5128-5136.
7. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
8. Bridgeman JS, Hawkins RE, Bagley S, Blaylock M, Holland M, Gilham DE. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 2010; 184: 6938-6949.
9. Altvater B, Landmeier S, Pscherer S, Temme J, Juergens H, Pule M et al. 2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells. Cancer Immunol Immunother 2009; 58: 1991-2001.
10. Zhong XS, Matsushita M, Plotkin J, Riviere I, Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8 T cell-mediated tumor eradication. Mol Ther 2010; 18: 413-420.
11. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
12. Cho SG, Yi Z, Pang X, Yi T, Wang Y, Luo J et al. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res 2009; 69: 7062-7070.
13. Grothey A, Galanis E. Targeting angiogenesis: Progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009; 6: 507-518.
14. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007; 16: 83-107.
15. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143: 1255-1262.
16. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993; 53: 5822-5827.
17. Brown LF, Olbricht SM, Berse B, Jackman RW, Matsueda G, Tognazzi KA et al. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol 1995; 154: 2801-2807.
18. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56: 1324-1330.
19. Kanagawa N, Yanagawa T, Mukai Y, Yoshioka Y, Okada N, Nakagawa S et al. Tumor-targeting CTL expressing a single-chain Fv specific for VEGFR2. Biochem Biophys Res Commun 2010; 394: 54-58.
20. Morita S, Kojima T, Kitamura T. Plat-E: An efficient and stable system for transient packaging of retroviruses. Gene Ther 2000; 7: 1063-1066.
21. Kataoka H, Takakura N, Nishikawa S, Tsuchida K, Kodama H, Kunisada T et al. Expressions of PDGF receptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5 define distinct subsets of nascent mesodermal cells. Dev Growth Differ 1997; 39: 729-740.
22. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T et al. Retrovirusmediated gene transfer and expression cloning: Powerful tools in functional genomics. Exp Hematol 2003; 31: 1007-1014.
23. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8 T cell-mediated insulin-dependent diabetes mellitus. J Immunol 1999; 163: 4335-4341.
24. Dace DS, Chen PW, Niederkorn JY. CD8 T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism. J Immunol 2007; 178: 6115-6122.
25. Griffioen AW, Molema G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000; 53: 237-268.
26. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
27. Zhang N, Fang Z, Contag PR, Purchio AF, West DB. Tracking angiogenesis induced by skin wounding and contact hypersensitivity using a Vegfr2-luciferase transgenic mouse. Blood 2004; 103: 617-626.
28. Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006; 47: 2048-2056.
29. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
30. Sadelain M, Rivie're I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35-45.
31. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-5218.
32. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-787.
33. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2010; 3: 24-40.
34. Crawford Y, Ferrara N. VEGF inhibition: Insights from preclinical and clinical studies. Cell Tissue Res 2009; 335: 261-269.
35. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
36. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70: 6171-6180.
37. Acuto O, Michel F. CD28-mediated co-stimulation: A quantitative support for TCR signaling. Nat Rev Immunol 2003; 3: 939-951.
38. Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C et al. Tumorspecific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2010; 167: 6123-6131.
39. Maher J, Brentjens RJ, Gunset G, Rivie' re I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2005; 20: 70-75.
40. Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest 2010; 120: 3953-3968.
41. Xu J, Grewal IS, Geba GP, Flavell RA. Impaired primary T cell responses in L-selectin-deficient mice. J Exp Med 1996; 183: 589-598.
42. Ku? ndig TM, Shahinian A, Kawai K, Mittru? cker HW, Sebzda E, Bachmann MF et al. Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity 1996; 5: 41-52.
43. Fuse S, Zhang W, Usherwood EJ. Control of memory CD8 T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response. J Immunol 2008; 180: 1148-1157.
44. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-618.